3546 results for «217»
3546 results
Breakthrough studies: Key abstracts on PCI, TAVI and mitral valve repair
04 Oct 2024 – From AICT-AsiaPCR 2024
Discover the cutting-edge research and innovative solutions presented in the 'Best Abstracts of AICT-AsiaPCR 2024' session. This curated selection showcases the latest advancements in interventional cardiology, from groundbreaking comparisons of transcatheter mitral valve repair techniques to the impact of cerebral embolic protection devices in TAVI procedures....
Managing severe calcified LAD lesions in STEMI: Insights from three cases
04 Oct 2024 – From AICT-AsiaPCR 2024
Dive into this compelling presentation highlighting three challenging STEMI cases involving severe proximal LAD calcified stenosis. Witness the ingenuity of interventional strategies as the presenter explores how drug-coated balloons can be a viable alternative to stents in acute MI management. Don't miss this opportunity to deepen...
POPular TAVI - Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients With a Long-Term Indication for Oral Anticoagulation
04 Apr 2020
The POPular TAVI trial is an open label randomized study designed to evaluate oral anticoagulation (OAC) alone compared with OAC plus clopidogrel for 3 months in patients undergoing transcatheter aortic valve replacement (TAVR) with a long-term indication for oral anticoagulation. Those who had undergone percutaneous revascularization...
Author
PANTHER - P2Y12 inhibitor versus aspirin monotherapy in patients with coronary artery disease
30 Aug 2022
Elad Asher provides his take on the PANTHER trial which was presented at the ESC Congress 2022 in Barcelona
Author
TRIGISTRY: Benefit of isolated surgical valve repair or replacement for functional tricuspid regurgitation and long-term outcomes stratified by the TRI-SCORE
31 Aug 2024
Alex Sticchi provides his take on the TRIGISTRY study presented by Julien Dreyfus at the ESC Congress 2024 in London.
Simultaneous publication in European Heart Journal, ehae578
Author
EuroPCR 2024: Elixir Medical’s late-breaking 12-month data demonstrate significant improvement in safety and effectiveness of world’s first site-specific antithrombotic therapeutic compared to DES
14 May 2024
